Which has higher earnings & valuation, RMD or GMED?

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ResMed $5.15B 5.71 $1.40B $10.37 19.54 Globus Medical $2.94B 3.72 $537.87M $4.30 18.73

Is RMD or GMED more profitable?

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets ResMed 27.44% 25.35% 18.69% Globus Medical 18.92% 13.46% 11.65%

Does the media prefer RMD or GMED?

In the previous week, ResMed had 3 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for ResMed and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat ResMed's score of 0.70 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ResMed 10 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Globus Medical 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, GMED or DXCM?

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.72 $537.87M $4.30 18.73 DexCom $4.66B 6.45 $836.30M $2.34 33.32

Is GMED or DXCM more profitable?

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% DexCom 19.31% 33.33% 13.19%

Does the media prefer GMED or DXCM?

In the previous week, DexCom had 4 more articles in the media than Globus Medical. MarketBeat recorded 19 mentions for DexCom and 15 mentions for Globus Medical. DexCom's average media sentiment score of 0.97 beat Globus Medical's score of 0.79 indicating that DexCom is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive DexCom 7 Very Positive mention(s) 2 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, GMED or STE?

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.72 $537.87M $4.30 18.73 STERIS $5.94B 3.63 $782.30M $7.93 27.88

Is GMED or STE more profitable?

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% STERIS 13.18% 14.15% 9.52%

Does the media favor GMED or STE?

In the previous week, Globus Medical had 9 more articles in the media than STERIS. MarketBeat recorded 15 mentions for Globus Medical and 6 mentions for STERIS. STERIS's average media sentiment score of 1.68 beat Globus Medical's score of 0.79 indicating that STERIS is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive STERIS 5 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor BAX or GMED?

In the previous week, Baxter International had 4 more articles in the media than Globus Medical. MarketBeat recorded 19 mentions for Baxter International and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Baxter International's score of 0.05 indicating that Globus Medical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Baxter International 8 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Globus Medical 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, GMED or PODD?

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Globus Medical $2.94B 3.72 $537.87M $4.30 18.73 Insulet $2.71B 4.21 $247.10M $4.30 38.24

Is GMED or PODD more profitable?

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity. Company Net Margins Return on Equity Return on Assets Globus Medical 18.92% 13.46% 11.65% Insulet 10.44% 26.87% 12.01%

Does the media refer more to GMED or PODD?

In the previous week, Insulet had 27 more articles in the media than Globus Medical. MarketBeat recorded 42 mentions for Insulet and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Insulet's score of 0.14 indicating that Globus Medical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Globus Medical 6 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Insulet 6 Very Positive mention(s) 1 Positive mention(s) 31 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Globus Medical (GMED) Competitors

$80.52 +1.96 (+2.50%)

Closing price 07/16/2026 03:59 PM Eastern

Extended Trading

$81.03 +0.51 (+0.63%)

As of 09:03 AM Eastern

Compare

GMED vs. RMD, DXCM, STE, BAX, and PODD

Should you buy Globus Medical stock or one of its competitors? MarketBeat compares Globus Medical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Globus Medical include ResMed (RMD), DexCom (DXCM), STERIS (STE), Baxter International (BAX), and Insulet (PODD). These companies are all part of the "health care equipment" industry.

How does Globus Medical compare to ResMed?

ResMed (NYSE:RMD) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, institutional ownership, earnings, media sentiment, valuation, risk and analyst recommendations.

ResMed currently has a consensus price target of $250.00, suggesting a potential upside of 23.36%. Globus Medical has a consensus price target of $103.75, suggesting a potential upside of 28.85%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts clearly believe Globus Medical is more favorable than ResMed.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ResMed	0 Sell rating(s)	9 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.53
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81

ResMed has a net margin of 27.44% compared to Globus Medical's net margin of 18.92%. ResMed's return on equity of 25.35% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ResMed	27.44%	25.35%	18.69%
Globus Medical	18.92%	13.46%	11.65%

ResMed has a beta of 0.78, indicating that its share price is 22% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

55.0% of ResMed shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.7% of ResMed shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

ResMed has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than ResMed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ResMed	$5.15B	5.71	$1.40B	$10.37	19.54
Globus Medical	$2.94B	3.72	$537.87M	$4.30	18.73

In the previous week, ResMed had 3 more articles in the media than Globus Medical. MarketBeat recorded 18 mentions for ResMed and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat ResMed's score of 0.70 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ResMed	10 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Globus Medical	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ResMed beats Globus Medical on 9 of the 17 factors compared between the two stocks.

How does Globus Medical compare to DexCom?

Globus Medical (NYSE:GMED) and DexCom (NASDAQ:DXCM) are both large-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

DexCom has a net margin of 19.31% compared to Globus Medical's net margin of 18.92%. DexCom's return on equity of 33.33% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
DexCom	19.31%	33.33%	13.19%

DexCom has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than DexCom, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.72	$537.87M	$4.30	18.73
DexCom	$4.66B	6.45	$836.30M	$2.34	33.32

Globus Medical currently has a consensus target price of $103.75, indicating a potential upside of 28.85%. DexCom has a consensus target price of $85.36, indicating a potential upside of 9.46%. Given Globus Medical's higher possible upside, analysts clearly believe Globus Medical is more favorable than DexCom.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
DexCom	1 Sell rating(s)	3 Hold rating(s)	21 Buy rating(s)	2 Strong Buy rating(s)	2.89

95.2% of Globus Medical shares are held by institutional investors. Comparatively, 97.8% of DexCom shares are held by institutional investors. 18.4% of Globus Medical shares are held by insiders. Comparatively, 0.3% of DexCom shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, DexCom had 4 more articles in the media than Globus Medical. MarketBeat recorded 19 mentions for DexCom and 15 mentions for Globus Medical. DexCom's average media sentiment score of 0.97 beat Globus Medical's score of 0.79 indicating that DexCom is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
DexCom	7 Very Positive mention(s)	2 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Globus Medical has a beta of 0.95, suggesting that its stock price is 5% less volatile than the broader market. Comparatively, DexCom has a beta of 1.45, suggesting that its stock price is 45% more volatile than the broader market.

Summary

DexCom beats Globus Medical on 13 of the 16 factors compared between the two stocks.

How does Globus Medical compare to STERIS?

Globus Medical (NYSE:GMED) and STERIS (NYSE:STE) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, media sentiment, profitability, institutional ownership, valuation and earnings.

95.2% of Globus Medical shares are owned by institutional investors. Comparatively, 94.7% of STERIS shares are owned by institutional investors. 18.4% of Globus Medical shares are owned by company insiders. Comparatively, 1.1% of STERIS shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Globus Medical has a net margin of 18.92% compared to STERIS's net margin of 13.18%. STERIS's return on equity of 14.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
STERIS	13.18%	14.15%	9.52%

STERIS has higher revenue and earnings than Globus Medical. Globus Medical is trading at a lower price-to-earnings ratio than STERIS, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.72	$537.87M	$4.30	18.73
STERIS	$5.94B	3.63	$782.30M	$7.93	27.88

Globus Medical has a beta of 0.95, suggesting that its share price is 5% less volatile than the broader market. Comparatively, STERIS has a beta of 0.92, suggesting that its share price is 8% less volatile than the broader market.

In the previous week, Globus Medical had 9 more articles in the media than STERIS. MarketBeat recorded 15 mentions for Globus Medical and 6 mentions for STERIS. STERIS's average media sentiment score of 1.68 beat Globus Medical's score of 0.79 indicating that STERIS is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
STERIS	5 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Globus Medical currently has a consensus target price of $103.75, suggesting a potential upside of 28.85%. STERIS has a consensus target price of $278.00, suggesting a potential upside of 25.72%. Given Globus Medical's stronger consensus rating and higher possible upside, equities analysts clearly believe Globus Medical is more favorable than STERIS.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
STERIS	0 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.75

Summary

Globus Medical beats STERIS on 11 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Baxter International?

Baxter International (NYSE:BAX) and Globus Medical (NYSE:GMED) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability and institutional ownership.

Baxter International presently has a consensus target price of $19.91, indicating a potential downside of 14.77%. Globus Medical has a consensus target price of $103.75, indicating a potential upside of 28.85%. Given Globus Medical's stronger consensus rating and higher possible upside, analysts plainly believe Globus Medical is more favorable than Baxter International.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Baxter International	4 Sell rating(s)	7 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	1.85
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81

Globus Medical has a net margin of 18.92% compared to Baxter International's net margin of -9.70%. Baxter International's return on equity of 16.15% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Baxter International	-9.70%	16.15%	5.24%
Globus Medical	18.92%	13.46%	11.65%

90.2% of Baxter International shares are held by institutional investors. Comparatively, 95.2% of Globus Medical shares are held by institutional investors. 0.2% of Baxter International shares are held by insiders. Comparatively, 18.4% of Globus Medical shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Globus Medical has lower revenue, but higher earnings than Baxter International. Baxter International is trading at a lower price-to-earnings ratio than Globus Medical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Baxter International	$11.24B	1.07	-$957M	-$2.13	N/A
Globus Medical	$2.94B	3.72	$537.87M	$4.30	18.73

In the previous week, Baxter International had 4 more articles in the media than Globus Medical. MarketBeat recorded 19 mentions for Baxter International and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Baxter International's score of 0.05 indicating that Globus Medical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Baxter International	8 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Globus Medical	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Baxter International has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Globus Medical has a beta of 0.95, meaning that its stock price is 5% less volatile than the broader market.

Summary

Globus Medical beats Baxter International on 14 of the 17 factors compared between the two stocks.

How does Globus Medical compare to Insulet?

Globus Medical (NYSE:GMED) and Insulet (NASDAQ:PODD) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, media sentiment, institutional ownership, risk, valuation, dividends and profitability.

In the previous week, Insulet had 27 more articles in the media than Globus Medical. MarketBeat recorded 42 mentions for Insulet and 15 mentions for Globus Medical. Globus Medical's average media sentiment score of 0.79 beat Insulet's score of 0.14 indicating that Globus Medical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Globus Medical	6 Very Positive mention(s)	1 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Insulet	6 Very Positive mention(s)	1 Positive mention(s)	31 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Globus Medical has higher revenue and earnings than Insulet. Globus Medical is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Globus Medical	$2.94B	3.72	$537.87M	$4.30	18.73
Insulet	$2.71B	4.21	$247.10M	$4.30	38.24

95.2% of Globus Medical shares are held by institutional investors. 18.4% of Globus Medical shares are held by company insiders. Comparatively, 0.4% of Insulet shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Globus Medical has a net margin of 18.92% compared to Insulet's net margin of 10.44%. Insulet's return on equity of 26.87% beat Globus Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Globus Medical	18.92%	13.46%	11.65%
Insulet	10.44%	26.87%	12.01%

Globus Medical has a beta of 0.95, meaning that its share price is 5% less volatile than the broader market. Comparatively, Insulet has a beta of 1.11, meaning that its share price is 11% more volatile than the broader market.

Globus Medical presently has a consensus target price of $103.75, suggesting a potential upside of 28.85%. Insulet has a consensus target price of $235.25, suggesting a potential upside of 43.07%. Given Insulet's higher probable upside, analysts clearly believe Insulet is more favorable than Globus Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Globus Medical	0 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	2 Strong Buy rating(s)	2.81
Insulet	2 Sell rating(s)	4 Hold rating(s)	22 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Globus Medical and Insulet tied by winning 8 of the 16 factors compared between the two stocks.

Get Globus Medical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GMED and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GMED vs. The Competition

Export

Metric	Globus Medical	MED INSTRUMENTS Industry	Medical Sector	NYSE Exchange
Market Cap	$10.66B	$7.56B	$6.96B	$23.43B
Dividend Yield	N/A	1.33%	2.68%	4.19%
P/E Ratio	18.73	50.61	27.19	31.08
Price / Sales	3.72	80.49	574.55	19.91
Price / Cash	12.50	26.61	49.25	33.10
Price / Book	2.38	7.22	10.85	4.78
Net Income	$537.87M	$162.30M	$3.59B	$1.07B
7 Day Performance	3.00%	-1.31%	-1.94%	0.53%
1 Month Performance	6.96%	0.40%	2.20%	2.19%
1 Year Performance	39.89%	5.48%	23.81%	17.07%

Globus Medical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GMED Globus Medical	4.316 of 5 stars	$80.52 +2.5%	$103.75 +28.8%	+42.3%	$10.66B	$2.94B	18.73	6,000	News Coverage Analyst Forecast
RMD ResMed	4.7139 of 5 stars	$218.40 +4.2%	$270.82 +24.0%	-20.2%	$30.41B	$5.15B	21.06	10,600	Analyst Forecast High Trading Volume
DXCM DexCom	3.8672 of 5 stars	$72.38 +1.6%	$84.88 +17.3%	-7.3%	$27.49B	$4.66B	30.93	11,000	Analyst Forecast
STE STERIS	4.8623 of 5 stars	$213.32 -2.2%	$278.00 +30.3%	-2.8%	$21.27B	$5.94B	26.90	17,937	Positive News
BAX Baxter International	1.4405 of 5 stars	$22.57 -0.4%	$19.73 -12.6%	-17.7%	$11.70B	$11.24B	N/A	37,500	Trending News Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:GMED) was last updated on 7/17/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Globus Medical (GMED) Competitors

GMED vs. RMD, DXCM, STE, BAX, and PODD

How does Globus Medical compare to ResMed?

Summary

How does Globus Medical compare to DexCom?

Summary

How does Globus Medical compare to STERIS?

Summary

How does Globus Medical compare to Baxter International?

Summary

How does Globus Medical compare to Insulet?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Globus Medical (GMED) Competitors

GMED vs. RMD, DXCM, STE, BAX, and PODD

How does Globus Medical compare to ResMed?

Do analysts prefer RMD or GMED?

Is RMD or GMED more profitable?

Which has more risk and volatility, RMD or GMED?

Do institutionals & insiders have more ownership in RMD or GMED?

Which has higher earnings & valuation, RMD or GMED?

Does the media prefer RMD or GMED?

Summary

How does Globus Medical compare to DexCom?

Is GMED or DXCM more profitable?

Which has better valuation & earnings, GMED or DXCM?

Do analysts prefer GMED or DXCM?

Do insiders and institutionals have more ownership in GMED or DXCM?

Does the media prefer GMED or DXCM?

Which has more risk and volatility, GMED or DXCM?

Summary

How does Globus Medical compare to STERIS?

Do institutionals and insiders hold more shares of GMED or STE?

Is GMED or STE more profitable?

Which has higher earnings & valuation, GMED or STE?

Which has more risk & volatility, GMED or STE?

Does the media favor GMED or STE?

Do analysts prefer GMED or STE?

Summary

How does Globus Medical compare to Baxter International?

Do analysts recommend BAX or GMED?

Is BAX or GMED more profitable?

Do institutionals and insiders have more ownership in BAX or GMED?

Which has stronger earnings and valuation, BAX or GMED?

Does the media favor BAX or GMED?

Which has more risk and volatility, BAX or GMED?

Summary

How does Globus Medical compare to Insulet?

Does the media refer more to GMED or PODD?

Which has preferable earnings and valuation, GMED or PODD?

Do institutionals and insiders believe in GMED or PODD?

Is GMED or PODD more profitable?

Which has more volatility and risk, GMED or PODD?

Do analysts rate GMED or PODD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GMED vs. The Competition

Globus Medical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools